All In Biotech

Drug Trial Radar · NCT04855136

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

21

Actual

Start

Jun 1, 2021

Primary completion

Apr 25, 2025

Study completion Apr 25, 2025

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM. The following combinations will be * Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone) * Arm B will test bb2121 in combination with BMS-986405 (JSMD194) Combination agents being tested may be administered before, concurrently with and/or following (ie, maintenance) bb2121 infusion. The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.

Conditions

  • Multiple Myeloma

Interventions

  • BB2121Biological

    CAR T Cell Therapy

  • CC-220Drug

    Cereblon (CRBN) E3 ligase modulatory compound (CELMoD)

  • BMS-986405Drug

    gamma secretase inhibitor (GSI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Does Limiting Toxicity (DLT) rates _Phase 1Time frame: Up to 28 days from start of the combination therapy
  2. Complete Response Rate (CRR)_ Phase 2Time frame: Up to 24 months

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Local Institution - 117

    Birmingham, Alabama

  • Local Institution - 113

    San Francisco, California

  • Local Institution - 101

    Jacksonville, Florida

  • Local Institution - 104

    Atlanta, Georgia

  • Local Institution - 120

    Atlanta, Georgia

  • Local Institution - 114

    Chicago, Illinois

  • Local Institution - 108

    Boston, Massachusetts

  • Local Institution - 124

    Boston, Massachusetts

  • Local Institution - 109

    Hackensack, New Jersey

  • New York University Langone

    New York, New York

  • Local Institution - 110

    New York, New York

  • Local Institution - 111

    Charlotte, North Carolina

  • Local Institution - 118

    Philadelphia, Pennsylvania

  • Local Institution - 103

    Nashville, Tennessee

  • Local Institution - 107

    Houston, Texas

  • Local Institution - 201

    Pamplona, Spain

  • Local Institution - 202

    Salamanca, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.